Tranexamic acid is an active site inhibitor of urokinase plasminogen activator

Blood Adv. 2019 Mar 12;3(5):729-733. doi: 10.1182/bloodadvances.2018025429.

Guojie Wu^{1

2}, Blake A Mazzitelli^{1

2}, Adam J Quek^{1

2}, Matthew J Veldman^{1

2}, Paul J Conroy^{1

2}, Tom T Caradoc-Davies^{1

2

3}, Lisa M Ooms^{1

2}, Kellie L Tuck⁴, Jonathan G Schoenecker⁵, James C Whisstock^{1

2

6}, Ruby H P Law^{1

2}

¹ ARC Centre of Excellence in Advanced Molecular Imaging, and.
² Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia.
³ Australian Synchrotron, Clayton, Australia.
⁴ School of Chemistry, Monash University, Melbourne, Australia.
⁵ Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN; and.
⁶ South East University-Monash Joint Institute, Institute of Life Sciences, Southeast University, Nanjing, China.

Abstract

TXA is an active-site inhibitor of uPA.
TXA attenuates MDA-MB-231 BAG cell migration and inhibits endogenous uPA activity.